Emerging Company Profiles

Emerging Company Profile: The firm’s use of the CD2 co-stimulant in its T cell engager design could significantly boost anti-tumor efficacy while addressing T cell exhaustion, with a first-in-human trial planned for 2024.

Emerging Company Profile: Fresh from a $73m follow-on offering last year, the US biotech is readying its lead asset for a pivotal trial in ultra-rare but debilitating mineralization disorders that affect infants and children.

Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.

Emerging Company Profile: The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.

Emerging Company Profile: The US firm’s lead candidate contains a gold standard ADHD simulant packaged in a compressed tablet that releases the ingredient at timed intervals to address symptoms for up to 16 hours.

Emerging Company Profile: The UK biotech is working to expedite its portfolio of acquired drug candidates for cancer through the clinic before out-licensing to big pharma in a bid to bring patients the treatments they need sooner rather than later.

Emerging Company Profile: The US biotech is advancing its lead candidate into a Phase Ib psoriasis trial as it works to validate its bacterial metabolite-based drug platform, which exemplifies a new generation of microbiome technology.

Emerging Company Profile: The Scottish biotech is the only firm targeting the ANAX1 protein with plans to initiate a modular Phase I trial that could look at multiple tumor types before expanding to the autoimmune space.

Emerging Company Profile: The biotech plans to enter the clinic next year with a gene therapy targeting the E2F4 protein in the hopes of halting Alzheimer’s disease progression and restoring lost function.

The German biotech plans to prevent chemotherapy-induced hearing loss and treat chronic hearing loss by targeting a potassium channel in the ear’s sensory hair cells as it tackles a widespread but side-lined area.

Emerging Company Profile: Mini-proteins offer some of the capabilities of small molecules and antibodies with fewer limitations, Ordaõs claims. The biotech wants to lead a paradigm shift from discovery to design.

Emerging Company Profile: The Danish firm has achieved proof-of-mechanism for its first-in-class CIC-1 inhibitor asset in myasthenia gravis as it advances a pipeline of transformative therapies for rare neuromuscular disorders.